Novartis reported a sharp drop in third-quarter operating income after booking a $1.9 billion impairment related to a failed experimental drug trial, but the Swiss pharmaceutical giant still managed to raise its full-year core profit outlook, citing robust demand for its key medicines.
The company said reported operating income fell 61% in the third quarter, largely due to the one-time write-down tied to del-desiran, an experimental treatment for myotonic dystrophy, a rare genetic muscle disorder. Research and development spending also climbed during the period, adding to the pressure on the bottom line.
An impairment is an accounting charge that reflects a reduction in the value of an asset. In this case, Novartis determined that the failed trial meant the drug was unlikely to generate the expected future revenue, so it wrote down its value. Such charges are non-cash and don't directly affect a company's cash flow, but they do hit reported earnings.
What the trial failure means
Del-desiran was being developed as a potential therapy for myotonic dystrophy, a condition that causes progressive muscle weakness and can affect the heart and other organs. The trial failure is a setback for Novartis's pipeline, but it's not uncommon in drug development, where many experimental candidates fail in clinical trials.
For investors, the key takeaway is that the company's underlying business remains strong. Excluding the impairment and other one-time items, Novartis's core operating profit—a measure that strips out such charges—benefited from solid sales of its top-selling drugs, including treatments for heart failure, multiple sclerosis, and cancer.
Because of that strength, Novartis raised its full-year core profit guidance, signaling that management expects the momentum to continue through the rest of the year. This is a positive signal for shareholders, as it suggests the company's day-to-day operations are healthy despite the trial setback.
What it means for investors
For everyday investors, the Novartis story highlights an important distinction: reported earnings can be distorted by one-time items, while core or adjusted earnings give a clearer picture of ongoing business performance. When a company takes a large impairment, it's often a sign that a past investment didn't pan out, but it doesn't necessarily reflect the health of the core business.
Novartis's decision to raise guidance despite the write-down suggests that management is confident in the company's growth prospects. That confidence is likely based on strong demand for its existing drugs and a pipeline that still has other promising candidates.
Investors should also note that the stock market often looks past one-time charges, focusing instead on underlying trends. In this case, the market may view the impairment as a manageable setback, especially if the company continues to deliver strong sales growth.
That said, drug development is inherently risky, and failures like this can weigh on a company's long-term growth potential. Investors in pharmaceutical stocks should be prepared for such volatility, as clinical trial outcomes are unpredictable.
Looking ahead, analysts and investors will be watching Novartis's fourth-quarter results to see if the raised guidance is met. They'll also be monitoring the company's pipeline for other potential blockbusters, as well as any competitive pressures on its key drugs.
For context, other pharmaceutical companies have faced similar challenges. For instance, Roche's recent lung cancer drug trial success shows how a positive trial outcome can lift a company's stock, while a failure can have the opposite effect.
Novartis's experience also underscores the importance of diversification in a portfolio. Holding a mix of sectors and companies can help cushion the impact of any single company's setbacks.
In the end, Novartis's third-quarter report is a reminder that headline numbers can be misleading. By looking beyond the impairment and focusing on the company's core performance, investors can get a more accurate picture of its financial health.
